

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * PATRICK GREGORY S (Last) (First) (Middle) C/O SUPERNUS PHARMACEUTICALS, INC. 1550 EAST GUDE DRIVE (Street) ROCKVILLE MD 20850 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS INC [SUPN]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) VP, Chief Financial Officer
	3. Date of Earliest Transaction (Month/Day/Year) 09/07/2017	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/07/2017		M ⁽¹⁾		26,519	A	\$7.9	27,235 ⁽²⁾	D	
Common Stock	09/07/2017		S ⁽¹⁾		25,000	D	\$46.3561 ⁽³⁾	2,235	D	
Common Stock	09/07/2017		S ⁽¹⁾		1,519	D	\$48	716	D	
Common Stock	09/07/2017		M ⁽¹⁾		15,000	A	\$5.88	15,716	D	
Common Stock	09/08/2017		M ⁽¹⁾		23,481	A	\$7.9	39,197	D	
Common Stock	09/08/2017		S ⁽¹⁾		23,481	D	\$48.8891 ⁽⁴⁾	15,716	D	
Common Stock	09/08/2017		M ⁽¹⁾		15,000	A	\$5.88	30,716	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Employee Stock Option (Right to Buy)	\$7.9	09/07/2017		M ⁽¹⁾			26,519	(5)	02/05/2023	Common Stock	26,519	\$0	43,481	D	
Employee Stock Option (Right to Buy)	\$5.88	09/07/2017		M ⁽¹⁾			15,000	(6)	12/30/2021	Common Stock	15,000	\$0	40,000	D	
Employee Stock Option (Right to Buy)	\$7.9	09/08/2017		M ⁽¹⁾			23,481	(5)	02/05/2023	Common Stock	23,481	\$0	20,000	D	
Employee Stock Option (Right to Buy)	\$5.88	09/08/2017		M ⁽¹⁾			15,000	(6)	12/30/2021	Common Stock	15,000	\$0	25,000	D	

Explanation of Responses:

- Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017.
- Includes an aggregate of 495 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$46.0000 to \$47.3500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$48.6000 to \$49.3500, inclusive. The reporting person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
- The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted.

6. The option became exercisable in four equal installments beginning on December 30, 2012, which was the first anniversary of the date on which the option was granted.

/s/ Gregory S. Patrick

09/11/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.